CSPC Pharmaceutical (1093 HK): Finished Drugs Drag 1Q25; Out Licensing And New Launches To Be Key
CSPC Pharmaceutical's 1Q25 revenue dropped 22% YoY, but operating margin remained stable. License and collaboration for pipeline products should...
596 Views
China Healthcare Weekly (May.18) - Trump to Lower US Drug Prices, Thoughts on Hengrui's IPO Pricing
Hengrui's HK IPO debut is strong, driven by positive sentiment for AH listing and the small IPO size (225 million circulating shares). Investors...
720 Views
Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey
Jiangsu Hengrui Pharmaceuticals (1276 HK) (JHP, 600276 CH ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing....
417 Views
Jiangsu Hengrui Pharma H Share Listing (1276 HK): Trading Debut
Hengrui had the highest oversubscription rates among recent large AH listings. The AH discount implied by the offer is attractive.
645 Views
PegBio 派格生物 IPO: A Hardsell but Mostly Done Deal
China-based biotech company PegBio launches IPO in Hong Kong to raise up to US$39m, with demanding valuation but support from local government for...
697 Views